<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938183</url>
  </required_header>
  <id_info>
    <org_study_id>MTZ085-2006</org_study_id>
    <nct_id>NCT01938183</nct_id>
  </id_info>
  <brief_title>Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis</brief_title>
  <official_title>Full-mouth Periodontal Debridement With or Without Adjunctive Metronidazole Gel in Smoking Patients With Chronic Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculty Sao Leopoldo Mandic Campinas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: metronidazole gel applied topically after periodontal debridement in smokers&#xD;
      volunteers could improve clinical parameters when compared to metronidazole tablets +&#xD;
      periodontal debridement. Method: 30 smokers with chronic periodontitis were randomly assigned&#xD;
      into 3 groups: periodontal debridement combined with 3 g placebo gel; periodontal debridement&#xD;
      combined with daily topical application of 3 g metronidazole benzoate gel (15%); and&#xD;
      periodontal debridement combined with a daily single dose of 750 mg metronidazole. Clinical&#xD;
      parameters evaluated were visible plaque, gingival bleeding, probing pocket depth and&#xD;
      relative attachment level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. The benefit of adjunctive metronidazole on periodontal procedure in smokers with&#xD;
      chronic periodontitis (CP) is uncertain. The authors compared the effect of metronidazole&#xD;
      (Mtz) on full-mouth periodontal debridement (PD= 1 hour of ultrasonic calculus/plaque&#xD;
      removal) in smokers with CP.&#xD;
&#xD;
      Methods. This pilot study involved 30 Individuals (having at least six teeth with a clinical&#xD;
      attachment loss of ≥ 5 mm and probing pocket depth (PPD) of ≥5 mm) that were randomly&#xD;
      assigned into three groups (n=10): 1) PD plus 3 g of placebo gel daily topical application 2)&#xD;
      PD plus daily topical application of 3 g of 15% Mtz benzoate gel; and 3) PD plus a daily&#xD;
      single dose of 750 mg Mtz (Flagyl®). Clinical parameters visible plaque index (VPI), gingival&#xD;
      bleeding index (GBI), relative attachment level (RAL) and PPD; and the quantitative analysis&#xD;
      (real-time PCR) of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and&#xD;
      Tannerella forsythia were assessed baseline, 1, 3 and 6 months after PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in PPD</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Probing pocket depth (PPD) measured from the bottom of the periodontal pocket to the gingival margin were considering four tooth surfaces: mesial, distal, buccal and lingual. Measurements were performed by a calibrated clinician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in microbiological biofilm composition</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Subgingival biofilm samples were collected from five pockets of each patient, present 5-6mm at the baseline period in a single root tooth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VPI</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Visible plaque index (VPI) measured on four tooth surfaces: mesial, distal, buccal and lingual. Measurements were performed by a calibrated clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in GBI</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Gingival bleeding index (GBI) measured on four tooth surfaces: mesial, distal, buccal and lingual. Measurements were performed by a calibrated clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RAL</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Relative attachment level (RAL) measured from the stent to the bottom of periodontal pocket. Measurements were performed by a calibrated clinician.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug use compliance</measure>
    <time_frame>After 8 days of periodontal treatment</time_frame>
    <description>Drug use compliance was measured by salivary drug concentration on the eighth day after periodontal debridement.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Full-mouth PD+placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full-mouth PD+Metronidazole tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Full-mouth PD+Metronidazole benzoate gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full-mouth periodontal debridement</intervention_name>
    <description>full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour</description>
    <arm_group_label>Full-mouth PD+Metronidazole benzoate gel</arm_group_label>
    <arm_group_label>Full-mouth PD+Metronidazole tablet</arm_group_label>
    <arm_group_label>Full-mouth PD+placebo gel</arm_group_label>
    <other_name>PD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole tablet</intervention_name>
    <description>750 mg metronidazole tablets</description>
    <arm_group_label>Full-mouth PD+Metronidazole tablet</arm_group_label>
    <other_name>MTZ tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>semi-solid suspension containing carbopol</description>
    <arm_group_label>Full-mouth PD+placebo gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole benzoate gel</intervention_name>
    <description>15% Mtz benzoate in semi-solid suspension containing carbopol (gel)</description>
    <arm_group_label>Full-mouth PD+Metronidazole benzoate gel</arm_group_label>
    <other_name>MTZ GEL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of chronic periodontitis&#xD;
&#xD;
          -  presence of at least 6 periodontal pockets with a clinical attachment loss of ≥5 mm&#xD;
&#xD;
          -  bleeding on probing (BOP)&#xD;
&#xD;
          -  radiographic bone loss&#xD;
&#xD;
          -  probing pocket depth higher or equal to 5 mm in at least six teeth&#xD;
&#xD;
          -  at least 20 teeth in mouth (third molars excluded)&#xD;
&#xD;
          -  an established smoking habit (at least 10 cigarettes per day for the past 4 years)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  periapical alterations in qualifying teeth&#xD;
&#xD;
          -  medical disorders requiring prophylactic antibiotic therapy or interfering with the&#xD;
             treatment&#xD;
&#xD;
          -  periodontal treatment in the past 6 months&#xD;
&#xD;
          -  use of drugs known to affect periodontal status (antibiotic, anti-inflammatory,&#xD;
             anticonvulsant, immunosuppressant and calcium channel blocker) within the past 6&#xD;
             months&#xD;
&#xD;
          -  orthodontic therapy&#xD;
&#xD;
          -  pregnancy and lactation&#xD;
&#xD;
          -  allergy to metronidazole&#xD;
&#xD;
          -  any systemic diseases (e.g.: diabetes and immunological disorders)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristiane C Bergamaschi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco C Groppo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Piracicaba Dental School</name>
      <address>
        <city>Piracicaba</city>
        <state>SP</state>
        <zip>13414903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Lorentz TC, Cota LO, Cortelli JR, Vargas AM, Costa FO. Prospective study of complier individuals under periodontal maintenance therapy: analysis of clinical periodontal parameters, risk predictors and the progression of periodontitis. J Clin Periodontol. 2009 Jan;36(1):58-67. doi: 10.1111/j.1600-051X.2008.01342.x. Epub 2008 Oct 30.</citation>
    <PMID>19017035</PMID>
  </reference>
  <reference>
    <citation>Carvalho LH, D'Avila GB, Leão A, Gonçalves C, Haffajee AD, Socransky SS, Feres M. Scaling and root planing, systemic metronidazole and professional plaque removal in the treatment of chronic periodontitis in a Brazilian population II--microbiological results. J Clin Periodontol. 2005 Apr;32(4):406-11.</citation>
    <PMID>15811059</PMID>
  </reference>
  <reference>
    <citation>Moeintaghavi A, Talebi-ardakani MR, Haerian-ardakani A, Zandi H, Taghipour S, Fallahzadeh H, Pakzad A, Fahami N. Adjunctive effects of systemic amoxicillin and metronidazole with scaling and root planing: a randomized, placebo controlled clinical trial. J Contemp Dent Pract. 2007 Jul 1;8(5):51-9.</citation>
    <PMID>17618330</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Francisco Groppo</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>chronic periodontitis</keyword>
  <keyword>metronidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

